The radical scavenger edaravone counteracts diabetes in multiple low-dose streptozotocin-treated mice

European Journal of Pharmacology

Volumn 583, Issue 1, 2008, Pages 164-169

  Fukudome, Daisuke ^a   Matsuda, Maki ^a   Kawasaki, Toshiyuki ^a   Ago, Yukio ^a   Matsuda, Toshio ^a  

^a OSAKA UNIVERSITY   (Japan)

Author keywords

Diabetes; Edaravone; Insulitis; Multiple low dose streptozotocin; Thiobarbituric acid reactive substance

Indexed keywords

HYDROXYL RADICAL; INSULIN; NORPHENAZONE; SCAVENGER; STREPTOZOCIN; THIOBARBITURIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DESTRUCTION; CELL INFILTRATION; CONTROLLED STUDY; DEGENERATIVE DISEASE; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG INHIBITION; HISTOCHEMISTRY; HYPERGLYCEMIA; IMMUNE SYSTEM; INSULIN DEPENDENT DIABETES MELLITUS; INSULITIS; LOW DRUG DOSE; MALE; MONONUCLEAR CELL; MOUSE; NONHUMAN; OXIDATIVE STRESS; PANCREAS; PANCREAS ISLET; PANCREAS ISLET BETA CELL; PATHOGENESIS; PRIORITY JOURNAL;

ANIMALS; ANTIPYRINE; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; FREE RADICAL SCAVENGERS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; LIPID PEROXIDATION; MALE; MICE; MICE, INBRED C57BL; PANCREAS; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 39649086267     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2008.01.033     Document Type: Article

References (45)

1. Andersson A.K., Flodström M., and Sandler S. Cytokine-induced inhibition of insulin release from mouse pancreatic β-cells deficient in inducible nitric oxide synthase. Biochem. Biophys. Res. Commun. 281 (2001) 396-403
2. Araki Y., Andoh A., Yokono T., Asano N., Yoshikawa K., Bamba S., and Fujiyama Y. The radical scavenger edaravone suppresses experimental closed duodenal loop-induced acute pancreatitis in rats. Int. J. Mol. Med. 12 (2003) 121-124
3. Chen H., Carlson E.C., Pellet L., Moritz J.T., and Epstein P.N. Overexpression of metallothionein in pancreatic β-cells reduces streptozotocin-induced DNA damage and diabetes. Diabetes 50 (2001) 2040-2046
4. Corbett J.A., and McDaniel M.L. Does nitric oxide mediate autoimmune destruction of β-cells? Possible therapeutic interventions in IDDM. Diabetes 41 (1992) 897-903
5. Eizirik D.L., and Pavlovic D. Is there a role for nitric oxide in β-cell dysfunction and damage in IDDM?. Diabetes Metab. Rev. 13 (1997) 293-307
6. Flodström M., Tyrberg B., Eizirik D.L., and Sandler S. Reduced sensitivity of inducible nitric oxide synthase-deficient mice to multiple low-dose streptozotocin-induced diabetes. Diabetes 48 (1999) 706-713
7. Hayashi T., Mori T., Sohmiya K., Okada Y., Inamoto S., Okuda N., Mori H., and Kitaura Y. Efficacy of edaravone, a free radical scavenger, on left ventricular function and structure in diabetes mellitus. J. Cardiovasc. Pharmacol. 41 (2003) 923-929
8. Heineke E.W., Johnson M.B., Dillberger J.E., and Robinson K.M. Antioxidant MDL 29,311 prevents diabetes in nonobese diabetic and multiple low-dose STZ-injected mice. Diabetes 42 (1993) 1721-1730
9. Holstad M., and Sandler S. Aminoguanidine, an inhibitor of nitric oxide formation, fails to protect against insulitis and hyperglycemia induced by multiple low dose streptozotocin injections in mice. Autoimmunity 15 (1993) 311-314
10. Hotta M., Tashiro F., Ikegami H., Niwa H., Ogihara T., Yodoi J., and Miyazaki J. Pancreatic β cell-specific expression of thioredoxin, an antioxidative and antiapoptotic protein, prevents autoimmune and streptozotocin-induced diabetes. J. Exp. Med. 188 (1998) 1445-1451
11. Houkin K., Nakayama N., Kamda K., Noujou T., Abe H., and Kashiwaba T. Neuroprotective effects of the free radical scavenger MCI-186 in patients with cerebral infarction: clinical evaluation using magnetic resonance imaging and spectroscopy. J. Stroke Cerebrovas. Dis. 7 (1998) 315-322
12. Ihara Y., Yamada Y., Toyokuni S., Miyawaki K., Ban N., Adachi T., Kuroe A., Iwakura T., Kubota A., Hiai H., and Seino Y. Antioxidant α-tocopherol ameliorates glycemic control of GK rats, a model of type 2 diabetes. FEBS Lett. 473 (2000) 24-26
13. Kajimoto Y., and Kaneto H. Role of oxidative stress in pancreatic β-cell dysfunction. Ann. N.Y. Acad. Sci. 1011 (2004) 168-176
14. Karabatas L.M., Pastorale C., de Bruno L.F., Maschi F., Pivetta O.H., Lombardo Y.B., Chemes H., and Basabe J.C. Early manifestations in multiple-low-dose streptozotocin-induced diabetes in mice. Pancreas 30 (2005) 318-324
15. Kawai H., Nakai H., Suga M., Yuki S., Watanabe T., and Saito K. Effects of a novel free radical scavenger, MCI-186, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. J. Pharmacol. Exp. Ther. 281 (1997) 921-927
16. Kawasaki T., Ishihara K., Ago Y., Nakamura S., Itoh S., Baba A., and Matsuda T. Protective effect of the radical scavenger edaravone against methamphetamine-induced dopaminergic neurotoxicity in mouse striatum. Eur. J. Pharmacol. 542 (2006) 92-99
17. Kawasaki T., Ishihara K., Ago Y., Baba A., and Matsuda T. Edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in the substantia nigra but not the striatum. J. Pharmacol. Exp. Ther. 322 (2007) 274-281
18. Kawasaki T., Kitao T., Nakagawa K., Fujisaki H., Takegawa Y., Koda K., Ago Y., Baba A., and Matsuda T. Nitric oxide-induced apoptosis in cultured rat astrocytes: protection by edaravone, a radical scavenger. Glia 55 (2007) 1325-1333
19. Kolb H., Kiesel U., Kröncke K.D., and Kolb-Bachofen V. Suppression of low dose streptozotocin induced diabetes in mice by administration of a nitric oxide synthase inhibitor. Life Sci. 49 (1991) PL213-PL217
20. Kubisch H.M., Wang J., Bray T.M., and Phillips J.P. Targeted overexpression of Cu/Zn superoxide dismutase protects pancreatic β-cells against oxidative stress. Diabetes 46 (1997) 1563-1566
21. Lakey J.R., Suarez-Pinzon W.L., Strynadka K., Korbutt G.S., Rajotte R.V., Mabley J.G., Szabó C., and Rabinovitch A. Peroxynitrite is a mediator of cytokine-induced destruction of human pancreatic islet β cells. Lab. Invest 81 (2001) 1683-1692
22. Lenzen S., Drinkgern J., and Tiedge M. Low antioxidant enzyme gene expression in pancreatic islets compared with various other mouse tissues. Free Radic. Biol. Med. 20 (1996) 463-466
23. Li Z., Karlsson F.A., and Sandler S. Islet loss and alpha cell expansion in type 1 diabetes induced by multiple low-dose streptozotocin administration in mice. J. Endocrinol. 165 (2000) 93-99
24. ω-nitro-l-arginine methyl ester reduces the incidence of IDDM in BB/E rats. Diabetes 44 (1995) 365-368
25. Lukic M.L., Stosic-Grujicic S., Ostojic N., Chan W.L., and Liew F.Y. Inhibition of nitric oxide generation affects the induction of diabetes by streptozocin in mice. Biochem. Biophys. Res. Commun. 178 (1991) 913-920
26. Mabley J.G., Southan G.J., Salzman A.L., and Szabó C. The combined inducible nitric oxide synthase inhibitor and free radical scavenger guanidinoethyldisulfide prevents multiple low-dose streptozotocin-induced diabetes in vivo and interleukin-1β-induced suppression of islet insulin secretion in vitro. Pancreas 28 (2004) E39-E44
27. Mendola J., Wright J.R., and Lacy P.E. Oxygen free-radical scavengers and immune destruction of murine islets in allograft rejection and multiple low-dose streptozocin-induced insulitis. Diabetes 38 (1989) 379-385
28. Oberley L.W. Free radicals and diabetes. Free Radic. Biol. Med. 5 (1988) 113-124
29. Papaccio G., Baccari G.C., Frascatore S., Sellitti S., and Pisanti F.A. The vitamin-E derivative U-83836-E in the low-dose streptozocin-treated mouse: effects on diabetes development. Diabetes Res. Clin. Pract. 30 (1995) 163-171
30. Papaccio G., Esposito V., Latronico M.V., and Pisanti F.A. Administration of a nitric oxide synthase inhibitor does not suppress low-dose streptozotocin-induced diabetes in mice. Int. J. Pancreatol. 17 (1995) 63-68
31. Papaccio G., Pisanti F.A., Latronico M.V., Ammendola E., and Galdieri M. Multiple low-dose and single high-dose treatments with streptozotocin do not generate nitric oxide. J. Cell Biochem. 77 (2000) 82-91
32. Rabinovitch A., and Suarez-Pinzon W.L. Cytokines and their roles in pancreatic islet β-cell destruction and insulin-dependent diabetes mellitus. Biochem. Pharmacol. 55 (1998) 1139-1149
33. Rydgren T., and Sandler S. Efficacy of 1400 W, a novel inhibitor of inducible nitric oxide synthase, in preventing interleukin-1β-induced suppression of pancreatic islet function in vitro and multiple low-dose streptozotocin-induced diabetes in vivo. Eur. J. Endocrinol 147 (2002) 543-551
34. Sandler S., and Andersson A. The partial protective effect of the hydroxyl radical scavenger dimethyl urea on streptozotocin-induced diabetes in the mouse in vivo and in vitro. Diabetologia 23 (1982) 374-378
35. Satoh K., Ikeda Y., Shioda S., Tobe T., and Yoshikawa T. Edarabone scavenges nitric oxide. Redox Rep. 7 (2002) 219-222
36. Song E.K., Hur H., and Han M.K. Epigallocatechin gallate prevents autoimmune diabetes induced by multiple low doses of streptozotocin in mice. Arch. Pharm. Res. 26 (2003) 559-563
37. Southern C., Schulster D., and Green I.C. Inhibition of insulin secretion by interleukin-1β and tumour necrosis factor-α by an l-arginine-dependent nitric oxide generating mechanism. FEBS Lett. 276 (1990) 42-44
38. Szabó C., Mabley J.G., Moeller S.M., Shimanovich R., Pacher P., Virág L., Soriano F.G., Van Duzer J.H., Williams W., Salzman A.L., and Groves J.T. Part I: Pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: studies with FP15, a novel potent peroxynitrite decomposition catalyst. Mol. Med. 8 (2002) 571-580
39. Sternesjo J., Welsh N., and Sandler S. S-methyl-l-thiocitrulline counteracts interleukin 1β induced suppression of pancreatic islet function in vitro, but does not protect against multiple low-dose streptozotocin-induced diabetes in vivo. Cytokine 9 (1997) 352-359
40. Takamura T., Ando H., Nagai Y., Yamashita H., Nohara E., and Kobayashi K. Pioglitazone prevents mice from multiple low-dose streptozotocin-induced insulitis and diabetes. Diabetes Res. Clin. Pract. 44 (1999) 107-114
41. + T cells expressing identical endogenous TCR-α chains. J. Immunol. 157 (1996) 4726-4735
42. Watanabe T., Yuki S., Egawa M., and Nishi H. Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. J. Pharmacol. Exp. Ther. 268 (1994) 1597-1604
43. G-monomethyl-l-arginine on the onset of diabetes in the spontaneously diabetic BB rat. Diabetes 44 (1995) 360-364
44. Xu B., Moritz J.T., and Epstein P.N. Overexpression of catalase provides partial protection to transgenic mouse beta cells. Free Radic. Biol. Med. 27 (1999) 830-837
45. Yoneda Y., Uehara T., Yamasaki H., Kita Y., Tabuchi M., and Mori E. Hospital-based study of the care and cost of acute ischemic stroke in Japan. Stroke 34 (2003) 718-724